"Bureaucratic" Zoon leaves CBER (Center for Biologics Evaluation and Research) to return to NIH (National Institutes of Health)
This article was originally published in Clinica
Virologist Jesse Goodman has been named to replace Kathryn Zoon as director of US FDA's Center for Biologics Evaluation and Research (CBER). Dr Zoon, who announced her resignation on December 13, said she was driven away in part by the agency's recent decision to shift authority for therapeutic biologics to the FDA's drug centre.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.